BRCA2 and colorectal adenocarcinoma: Human colorectal adenocarcinoma BRCA2−/− DLD1 cells (Zimmer et al, 2016; Fig 1A) were hypersensitive to both drugs, when compared with BRCA2+/+ DLD1 cells.